Purpose Whilst the treatment paradigm for colorectal cancer has evolved significantly over
time, there is still a lack of reliable biomarkers of treatment response. Treatment decisions …

Metastatic dissemination represents a hallmark of cancer that is responsible for the high
mortality rate. Recently, emerging evidence demonstrates a time-series event—pre …

Simple Summary Immune checkpoint inhibitors (ICIs) are being increasingly used after
primary treatment of early-stage tumors to treat any residual disease and prevent …

Simple Summary The progression of pancreatic cancer (PDAC) involves a series of events
transforming the phenotype of cancer cells, namely epithelial-to-mesenchymal transition …

Background In the adjuvant setting of cancer treatment, de-escalation strategies have the
goal of omitting or minimizing treatment in patients, without compromising outcomes …

Programmed death-ligand 1 (PD-L1) is an immune checkpoint molecule that can regulate
immune responses in the tumor microenvironment (TME); however, the clinical applications …

Circulating tumor DNA (ctDNA) is a promising biomarker, reflecting the presence of tumor
cells. Sequencing-based detection of ctDNA at low tumor fractions is challenging due to the …

Surgery with or without adjuvant chemotherapy is the standard treatment for early-stage
colon cancer. However, evidence has recently emerged for neoadjuvant chemotherapy, with …

Cancer morbidity and mortality are growing rapidly worldwide and it is urgent to develop a
convenient and effective method that can identify cancer patients at an early stage and …

Background There is accumulating evidence supporting the clinical use of circulating tumor
DNA (ctDNA) in solid tumors, especially in different types of gastrointestinal cancer. As such …